A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center received a five-year, $2.5 million grant from NCI to develop a novel therapy to treat lung cancer.
Cristina Puig-Saus and Daniel Shin, of UCLA Jonsson Comprehensive Cancer Center have received a $1 million Translational Research Award from the U.S. Department of Defense Melanoma Research Program to help advance the use of chimeric antigen receptor, or CAR, T cell therapy as a treatment for people with acral, mucosal and uveal melanomas.
The first UAMS Baptist Health Cancer Center is now open on the campus of Baptist Health Medical Center in North Little Rock.
Stand Up To Cancer and Jazz Pharmaceuticals have entered into a three-year, $4 million research collaboration to research hard-to-treat cancers, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers.
The Cancer Prevention and Research Institute of Texas has awarded 73 new cancer research and prevention grants totaling over $142 million.
The Cancer Prevention and Research Institute of Texas has awarded eight grants totaling more than $13 million dedicated to expanding access to cancer clinical trials in Texas, including one new award that will strengthen clinical trial network infrastructure, two first-of-their-kind CPRIT awards to encourage increased participation in clinical trials and five awards that support the next generation of promising clinical investigators.
LUNGevity Foundation has issued a Requests for Application for two 2022 RET-positive lung cancer research award programs.
Research from a large international effort shows that 20% of children with cancer who are infected with SARS-CoV-2 develop severe infections.
The National Comprehensive Cancer Network has updated the NCCN: Cancer and COVID-19 Vaccination guidance with information on the third mRNA COVID-19 vaccine.
A study published in JNCCN—Journal of the National Comprehensive Cancer Network demonstrated that among all patients with neuroendocrine tumors, the risk of dying of cancer was higher than that of dying of other causes—but mortality varies by primary tumor site.
